Since targeted therapy provides higher success rates and reduced complications and toxicity in patients with advanced lung cancer and driver gene mutations (e.g., epidermal growth factor receptor [EGFR] mutation), identifying the relationship between CT morphological features and driver gene mutations in LADC may be advantageous for therapeutic decision-making in patients where obtaining pathologic specimens is difficult [12–14]. The gene discussed is EGFR; the disease is lung carcinoma.